Can [125I]-iodocyanopindolol label ß3-adrenoceptors in rat urinary bladder?

β3-Adrenoceptors have been demonstrated to mediate urinary bladder smooth muscle relaxation but proof of their expression at the protein level has been missing because of lack of suitable antibodies or radioligands. As among various available radioligands [125I]-iodocyanopindolol ([125I]-ICYP) exhib...

Full description

Bibliographic Details
Main Authors: Tim eSchneider, Martin Christian Michel
Format: Article
Language:English
Published: Frontiers Media S.A. 2010-10-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00128/full
_version_ 1828527967705235456
author Tim eSchneider
Martin Christian Michel
author_facet Tim eSchneider
Martin Christian Michel
author_sort Tim eSchneider
collection DOAJ
description β3-Adrenoceptors have been demonstrated to mediate urinary bladder smooth muscle relaxation but proof of their expression at the protein level has been missing because of lack of suitable antibodies or radioligands. As among various available radioligands [125I]-iodocyanopindolol ([125I]-ICYP) exhibited the smallest problems in labelling cloned human β3-adrenoceptors in previous studies, we have explored its suitability to label β3-adrenoceptors in rat urinary bladder in saturation and competition radioligand binding experiments. Rat lung was used as an internal control and exhibited all characteristics expected from this tissue with regard to β1/β2-adrenoceptor labelling. Saturation and competition binding studies with [125I]-ICYP in rat bladder yielded saturable binding sites with an affinity compatible with β3-adrenoceptors. In competition experiments various agonists and antagonists largely exhibited a profile compatible with a population consisting largely of β3-adrenoceptors. However, the binding competition properties of ICI 118,551 and SR 59,230A were not easily explained by the idea of labelling a homogeneous β3-adrenoceptor population but interpretation of the data was limited by a high degree of non-specific binding in [125I]-ICYP concentrations required to label the receptors. We conclude that [125I]-ICYP can be used to label tissue β3-adrenoceptors but results obtained with this ligand have to be interpreted with caution.
first_indexed 2024-12-11T21:45:36Z
format Article
id doaj.art-f3347ef733234fddb1d8c3b22338c50d
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-12-11T21:45:36Z
publishDate 2010-10-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-f3347ef733234fddb1d8c3b22338c50d2022-12-22T00:49:38ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122010-10-01110.3389/fphar.2010.001287200Can [125I]-iodocyanopindolol label ß3-adrenoceptors in rat urinary bladder?Tim eSchneider0Martin Christian Michel1University of EssenAcademic Medical Centerβ3-Adrenoceptors have been demonstrated to mediate urinary bladder smooth muscle relaxation but proof of their expression at the protein level has been missing because of lack of suitable antibodies or radioligands. As among various available radioligands [125I]-iodocyanopindolol ([125I]-ICYP) exhibited the smallest problems in labelling cloned human β3-adrenoceptors in previous studies, we have explored its suitability to label β3-adrenoceptors in rat urinary bladder in saturation and competition radioligand binding experiments. Rat lung was used as an internal control and exhibited all characteristics expected from this tissue with regard to β1/β2-adrenoceptor labelling. Saturation and competition binding studies with [125I]-ICYP in rat bladder yielded saturable binding sites with an affinity compatible with β3-adrenoceptors. In competition experiments various agonists and antagonists largely exhibited a profile compatible with a population consisting largely of β3-adrenoceptors. However, the binding competition properties of ICI 118,551 and SR 59,230A were not easily explained by the idea of labelling a homogeneous β3-adrenoceptor population but interpretation of the data was limited by a high degree of non-specific binding in [125I]-ICYP concentrations required to label the receptors. We conclude that [125I]-ICYP can be used to label tissue β3-adrenoceptors but results obtained with this ligand have to be interpreted with caution.http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00128/fullLungUrinary Bladderrat[125I]-iodocyanopindololβ3-adrenoceptor
spellingShingle Tim eSchneider
Martin Christian Michel
Can [125I]-iodocyanopindolol label ß3-adrenoceptors in rat urinary bladder?
Frontiers in Pharmacology
Lung
Urinary Bladder
rat
[125I]-iodocyanopindolol
β3-adrenoceptor
title Can [125I]-iodocyanopindolol label ß3-adrenoceptors in rat urinary bladder?
title_full Can [125I]-iodocyanopindolol label ß3-adrenoceptors in rat urinary bladder?
title_fullStr Can [125I]-iodocyanopindolol label ß3-adrenoceptors in rat urinary bladder?
title_full_unstemmed Can [125I]-iodocyanopindolol label ß3-adrenoceptors in rat urinary bladder?
title_short Can [125I]-iodocyanopindolol label ß3-adrenoceptors in rat urinary bladder?
title_sort can 125i iodocyanopindolol label ss3 adrenoceptors in rat urinary bladder
topic Lung
Urinary Bladder
rat
[125I]-iodocyanopindolol
β3-adrenoceptor
url http://journal.frontiersin.org/Journal/10.3389/fphar.2010.00128/full
work_keys_str_mv AT timeschneider can125iiodocyanopindolollabelß3adrenoceptorsinraturinarybladder
AT martinchristianmichel can125iiodocyanopindolollabelß3adrenoceptorsinraturinarybladder